Lymphoscintigraphy with 13I-labelled epidermal growth factor

Abstract

We have used 123I-labelled epidermal growth factor (EGF) scans to study 14 patients with advanced cervical cancer. Abnormal lymph node imaging was seen most clearly 6-8 h after the injection and revealed abnormal uptake by pelvic lymph nodes in 11 patients. 4 of these 11 had abnormal computerised tomographic and ultrasound scans; in the other 7 conventional radiology did not confirm the presence of disease.

Anilinodialkoxyquinazolines: Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Potential Tumor Imaging Probes

“…20 123 I-EGF has been used to image cervical cancer in humans. 21 In spite of its ability to localize in EGFR rich tissue, radioiodinated EGF rapidly degrades in vivo releasing radioiodine thereby reducing the lifetime of the label in the tumor. 22 Iodinated dextran-EGF conjugates increase retention of the iodine by tumor cells but at the cost of higher molecular weight that affects tracer distribution.…”

Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer

“…Several receptor-binding radiopharmaceuticals have been introduced for the in vivo evaluation of receptor density and binding affinity (Eckelman et al, 1979;Krenning et al, 1989;Wagner et al, 1983;Schatten et al, 1990;Pavlik et al, 1990;Virgolini et al, 1989b), and a variety of nuclear medicine techniques have been implemented to be useful in this aspect (Wagner et al, 1983;Vera et al, 1985;1991a;Farde et al, 1986;Logan et al, 1987). A valid analytic assessment of receptor biochemistry via kinetic modelling 1991a) was applied for this study.…”

“…These tracers have been successfully applied in oncology, such as for the detection of endocrine tumours using somatostatin analogs (Krenning et al, 1989), specific receptor radiotracers for the brain (Wagner et al, 1983), radiolabelled epidermal growth factor in gynaecology (Schatten et al, 1990), radiolabelled oestrogen analogs in breast cancer (Pavlik et al, 1990) or galactose-terminated neoglycoalbumin (NGA) in primary and secondary liver cancer (Virgolini et al, 1989b). 9'Tc-NGA is one of the first chemically synthetised receptor radiopharmaceuticals introduced for in vivo use in humans (Vera et al, 1984;Stadalnik et al, 1985;Virgolini et al, 1989aVirgolini et al, ,b, 1991Virgolini et al, , 1992.…”

Growth factors in bladder cancer

“…One approach is to target the tumor display of growth factor receptors. Because many bladder cancer cells overexpress EGFr, use of radiolabeled EGF or radiolabeled antiEGFr antibodies for the detection of tumor cells is the most direct application of this approach [37,94]. Bladder cancer xenografts is nude mice have been imaged using this technique with good target: background ratios [42].…”